Allos Therapeutics to Present at the 2007 JP Morgan Healthcare Conference
09 1월 2007 - 5:19AM
PR Newswire (US)
WESTMINSTER, Colo., Jan. 8 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced that the Company
will participate in the 2007 JP Morgan Healthcare Conference, to be
held January 8 -11 in San Francisco. Paul L. Berns, the Company's
President and Chief Executive Officer, will give a 30-minute
corporate overview on Wednesday, January 10 at 9:30 AM PT. Live and
archived web casts of the presentation will be available on the
Company's website: http://www.allos.com/. About Allos Therapeutics,
Inc. Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company
focused on the development and commercialization of small molecule
therapeutics for the treatment of cancer. The Company has two
product candidates in late-stage clinical development: EFAPROXYN
(efaproxiral), a radiation sensitizer currently under evaluation in
a pivotal Phase 3 trial in women with brain metastases originating
from breast cancer, and PDX (pralatrexate), a novel, next
generation antifolate currently under evaluation in a pivotal Phase
2 trial in patients with relapsed or refractory peripheral T-cell
lymphoma. The Company is also evaluating RH1, a targeted
chemotherapeutic agent, in a Phase 1 trial in patients with
advanced solid tumors. For additional information, please visit the
Company's website at http://www.allos.com/ Safe Harbor Statement
The anticipated presentations will contain forward-looking
statements that involve significant risks and uncertainties,
including those to be discussed in the presentations and others
that can be found in the "Risk Factors" section of the Company's
Form 10-K for the year ended December 31, 2005 and in the Company's
periodic reports on Form 10-Q and Form 8-K. The Company does not
undertake any obligation to update any forward-looking statements
contained in the anticipated presentations as a result of new
information, future events or otherwise. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in the presentation. No forward-looking
statement can be guaranteed and actual events and results may
differ materially from those projected. DATASOURCE: Allos
Therapeutics, Inc. CONTACT: Jennifer Neiman Manager, Corporate
Communications of Allos Therapeutics, +1-720-540-5227, Web site:
http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics (MM) News Articles